Burcu M - Search Results

1

The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR. Natarajan K, et al. Among authors: burcu m. Biochem Pharmacol. 2013 Feb 15;85(4):514-24. doi: 10.1016/j.bcp.2012.12.006. Epub 2012 Dec 19. Biochem Pharmacol. 2013. PMID: 23261525 Free PMC article.

2

Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia.

Burcu M, O'Loughlin KL, Ford LA, Baer MR. Burcu M, et al. Leukemia. 2008 Nov;22(11):2110-5. doi: 10.1038/leu.2008.87. Epub 2008 Apr 17. Leukemia. 2008. PMID: 18418409 No abstract available.

3

Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression.

Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Xie Y, et al. Among authors: burcu m. Mol Pharmacol. 2010 Aug;78(2):310-8. doi: 10.1124/mol.109.061713. Epub 2010 May 11. Mol Pharmacol. 2010. PMID: 20460432 Free PMC article.

4

Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.

Natarajan K, Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Natarajan K, et al. Among authors: burcu m. PLoS One. 2013 Sep 5;8(9):e74653. doi: 10.1371/journal.pone.0074653. eCollection 2013. PLoS One. 2013. PMID: 24040307 Free PMC article.

5

Response to Adesman and Blaufox re: "Stimulants and Pediatric Cardiovascular Risk".

Zito JM, Burcu M. Zito JM, et al. Among authors: burcu m. J Child Adolesc Psychopharmacol. 2017 Aug;27(6):560. doi: 10.1089/cap.2017.0067. J Child Adolesc Psychopharmacol. 2017. PMID: 28820638 No abstract available.

6

Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.

Zito JM, Burcu M, Ibe A, Safer DJ, Magder LS. Zito JM, et al. Among authors: burcu m. Psychiatr Serv. 2013 Mar 1;64(3):223-9. doi: 10.1176/appi.ps.201200081. Psychiatr Serv. 2013. PMID: 23242390

7

Construct validity and factor structure of survey-based assessment of cost-related medication burden.

Burcu M, Alexander GC, Ng X, Harrington D. Burcu M, et al. Med Care. 2015 Feb;53(2):199-206. doi: 10.1097/MLR.0000000000000286. Med Care. 2015. PMID: 25517070

8

Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications.

Burcu M, Zito JM, Ibe A, Safer DJ. Burcu M, et al. J Child Adolesc Psychopharmacol. 2014 Apr;24(3):112-9. doi: 10.1089/cap.2013.0094. Epub 2014 Apr 1. J Child Adolesc Psychopharmacol. 2014. PMID: 24690011

9

Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens.

Burcu M, Safer DJ, Zito JM. Burcu M, et al. Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):26-34. doi: 10.1002/pds.3897. Epub 2015 Oct 28. Pharmacoepidemiol Drug Saf. 2016. PMID: 26507224

10

Stimulants and Pediatric Cardiovascular Risk.

Zito JM, Burcu M. Zito JM, et al. Among authors: burcu m. J Child Adolesc Psychopharmacol. 2017 Aug;27(6):538-545. doi: 10.1089/cap.2015.0239. Epub 2016 Jun 3. J Child Adolesc Psychopharmacol. 2017. PMID: 27258470 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page